CEO Joaquin Duato said the company is positioned for sustained growth in coming years even as competition batters Stelara, ...

The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the Inflation Reduction Act.

The rescinded Biden-era orders include actions to boost the Affordable Care Act exchanges, coordinate the government’s ...